CJC/IPA Protocol vs TB-500
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC/IPA Protocol and TB-500 work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC/IPA Protocol TB-500
Weight N/A 4,963.44 Da
Half-life — ~2 hours
Chain N/A 43 amino acids
Type Peptide combination (GHRH analog + GHS) Thymosin fragment
Key Benefits
CJC/IPA Protocol
01 Sustained GH elevation (6-8 days from CJC-1295)
02 Selective pulsatile release without cortisol suppression
03 Complementary dual-pathway optimization
04 Preservation of natural GH rhythm
05 Enhanced muscle protein synthesis and recovery
TB-500
01 Superior systemic tissue repair
02 Accelerated muscle, tendon, and ligament healing
03 Enhanced cell migration and angiogenesis
04 Comprehensive regenerative effects
05 Neuroprotective properties
Dosing Protocols
CJC/IPA Protocol
200-300mcg of each peptide (CJC-1295 and Ipamorelin) / Once daily, preferably in the evening
General Health Optimization 200mcg each (0.2mL if 1mg/mL) Once daily
Performance Enhancement 250mcg each (0.25mL if 1mg/mL) Once daily
Recovery Optimization 300mcg each (0.3mL if 1mg/mL) Once daily
Conservative Approach 150mcg each (0.15mL if 1mg/mL) 5 days per week
TB-500
2-5mg per injection (higher doses for serious injuries) / 2-3x weekly (e.g., Monday, Wednesday, Friday)
General tissue repair 2-3mg 2x weekly
Serious injury recovery 4-5mg 3x weekly
Athletic enhancement 2-3mg 2x weekly
Chronic conditions 3-4mg 2-3x weekly
Maintenance 2mg 1-2x weekly
Post-surgical recovery 3-5mg 3x weekly
Side Effects
CJC/IPA Protocol
Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation
TB-500
Generally minimal side effects
Possible mild injection site reactions
Temporary fatigue in some users
Contraindications
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders
Active cancer treatment (due to angiogenic effects)
Pregnancy or breastfeeding
Immunosuppressive medications (consult provider)
WADA prohibited for competitive athletes
Research Evidence
CJC/IPA Protocol TB-500
Status Well Studied Well Studied
References 4 studies 6 studies
Latest June 2024 November 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.